紧抓大健康产业发展新机遇 东宝生物2024年实现营收8.85亿元

Core Viewpoint - Dongbao Bio achieved a revenue of 885 million yuan and a net profit of 85.98 million yuan in 2024, focusing on the "collagen+" strategy to develop a comprehensive health industry group covering various sectors [2][5]. Group 1: Business Strategy - The company is enhancing its core business around "natural collagen" while developing a comprehensive platform integrating R&D, production, and marketing [3]. - Dongbao Bio is deepening its strategic layout in the pharmaceutical, nutrition, and beauty sectors, while also building an online and offline integrated sales network [3][4]. - The company is expanding into emerging fields by innovating technology and exploring market demands, particularly in new materials applications [3][5]. Group 2: Acquisitions and Production Capacity - In 2024, Dongbao Bio acquired all minority shares of Qingdao Yiqing Biotechnology Co., enhancing its operational management and launching the "New Hollow Capsule Intelligent Industrialization Project" [4]. - The hollow capsule production capacity is expected to reach nearly 70 billion capsules annually after the completion of the expansion project, with a revenue growth of 19.05% in the capsule business [4][5]. Group 3: Market Trends and Innovations - The health awareness among consumers is increasing, leading to steady growth in demand for health foods and beauty products, supported by favorable policies for the health industry [5][6]. - Dongbao Bio is focusing on a dual-driven R&D model of "independent innovation + collaborative research," targeting biomedicine, health foods, and new materials [5][6]. - The company is expanding the application of its blood plasma gelatin into medical fields, including hemostatic materials and drug delivery systems [5][6].